Last checked at 15 Jan 2020 07:00
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms E Walmsley | |||
b) | Position/status | Chief Executive Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£17.9020 | 195 | ||||
£17.9020 | 195 | ||||
£17.9020 | 684 | ||||
£17.9020 | 680 | ||||
d) | Aggregated information
| 1,754 | |||
Aggregated volume Price | £17.9020 | ||||
e) | Date of the transaction | 2020-01-13 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R Connor
| |||
b) | Position/status | President, Global Vaccines | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£17.9020 | 101 | ||||
£17.9020 | 101 | ||||
£17.9020 | 144 | ||||
£17.9020 | 178 | ||||
d) | Aggregated information
| 524 | |||
Aggregated volume Price | £17.9020 | ||||
e) | Date of the transaction | 2020-01-13 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr N Hirons | |||
b) | Position/status | SVP, Global Ethics & Compliance | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£17.9020 | 64 | ||||
£17.9020 | 64 | ||||
£17.9020 | 75 | ||||
£17.9020 | 74 | ||||
d) | Aggregated information
| 277 | |||
Aggregated volume Price | £17.9020 | ||||
e) | Date of the transaction | 2020-01-13 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr L Miels | |||
b) | Position/status | President, Global Pharmaceuticals | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£17.9020 | 137 | ||||
£17.9020 | 190 | ||||
d) | Aggregated information
| 327 | |||
Aggregated volume Price | £17.9020 | ||||
e) | Date of the transaction | 2020-01-13 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr D Redfern | |||
b) | Position/status | Chief Strategy Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£17.9020 | 80 | ||||
£17.9020 | 80 | ||||
£17.9020 | 140 | ||||
£17.9020 | 168 | ||||
d) | Aggregated information
| 468 | |||
Aggregated volume Price | £17.9020 | ||||
e) | Date of the transaction | 2020-01-13 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr R Simard | |||
b) | Position/status | President, Pharmaceuticals Supply Chain | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£17.9020 | 61 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2020-01-13 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr P Thomson | |||
b) | Position/status | President, Global Affairs | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
| |||
b) | Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 9 January 2020 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
£17.9020 | 76 | ||||
£17.9020 | 95 | ||||
£17.9020 | 98 | ||||
d) | Aggregated information
| 269 | |||
Aggregated volume Price | £17.9020 | ||||
e) | Date of the transaction | 2020-01-13 | |||
f) | Place of the transaction
| London Stock Exchange (XLON) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr B McNamara | |||
b) | Position/status | CEO, GSK Consumer Healthcare | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| |||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 January 2020 on ADSs held in the Company's Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$46.6500 | 74 | ||||
$46.6500 | 72 | ||||
$46.6500 | 68 | ||||
d) | Aggregated information
| 214 | |||
Aggregated volume Price | $46.6500 | ||||
e) | Date of the transaction | 2020-01-13 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr H Barron | |||
b) | Position/status | Chief Scientific Officer and President, R&D | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| |||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 January 2020 on ADSs held in the Company's Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$46.6500 | 406 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2020-01-13 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr J Ford | |||
b) | Position/status | Senior Vice President and General Counsel | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| |||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 January 2020 on ADSs held in the Company's Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$46.6500 | 35 | ||||
d) | Aggregated information
| N/A (single transaction) | |||
Aggregated volume Price | |||||
e) | Date of the transaction | 2020-01-13 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms K Terrell | |||
b) | Position/status | Chief Digital & Technology Officer | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs') ISIN: US37733W1053
| |||
b) | Nature of the transaction | Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 9 January 2020 on ADSs held in the Company's Deferred Annual Bonus Plan. | |||
c) | Price(s) and volume(s) | Price(s) | Volume(s) | ||
$46.6500 | 24 | ||||
$46.6500 | 86 | ||||
d) | Aggregated information
| 110 | |||
Aggregated volume Price | $46.6500 | ||||
e) | Date of the transaction | 2020-01-13 | |||
f) | Place of the transaction
| New York Stock Exchange (XNYS) | |||